COVID19 pandemic currently represents a public health emergency. Based on current data, 15% of the affected individuals will develop a severe form of the disease requiring admission to hospital and respiratory support. Data show that age and cardiovascular pre-existing comorbidities predict a poorer outcome. Some evidence suggests that a subset of patients with poorer outcome present with a cytokine mediated inflammatory response and with a secondary HLH like clinical phenotype. No data are so far available with regard to the risk of severe COVID19 disease in the post stem cell transplantation setting. Recipients of allogeneic stem cell transplantation are by definition immunologically dysregulated and could potentially present with a unique immune-inflammatory response to COVID 19 infection. Moreover, the immunosuppression used to prevent/treat GVHD may also impact clinical progression and it is possible that because of their immunological defects, SCT patients could potentially have prolonged carriage of the virus and hence act as "super spreaders". The present study aims at documenting clinical and biological characteristics, including immunological profiling, of allogeneic stem cell transplant recipients presenting with severe COVID 19 infection and its impact on patients survival. This work may provide the scientific basis for targeted therapy with biological agents in this patient group.
The transplant teams in each participating site will be identifying and approaching eligible
patients. Adult and paediatric patients with a history of allogeneic stem cell
transplantation who are admitted to hospital with a proven severe COVID19 infection will be
eligible for the study. Within 72 hrs of admission, a 10 ml clotted blood (5 mls for pts
below 15 kg weight) will be collected and serum frozen at -80 C. This sample will be sent
with a 10ml blood sample (5 mls for pts below 15 kg weight) in EDTA to the Immunology
Laboratories at Great Ormond Street Hospital (GOSH) in London for centralized cytokine and
lymphocyte subset analysis. The sample will be divided into 2 aliquots, one being analyzed
directly, the second one being frozen for further assays as developed. Other immunological
and biochemical parameters will be tested locally and results with local reference ranges
will be collected for the purpose of the current study.
In case the patient deteriorates further from the respiratory perspective requiring either
CPAP or mechanical ventilation, a second 5 ml serum sample may be collected, frozen at -80 C
and sent to GOSH for repeated cytokine analysis.
HScore will be calculated as per published data but bone marrow aspiration will be optional
in calculating the scoring given the expected acute clinical situation of the patient.
(Fardet et al, Arthritis Rheumatol 2014).
Transplant research team members will collect demographic and clinical characteristics at the
time samples are sent to GOS. Blood results, data on clinical course, therapy (including
biological agents) and outcome data will be collected with a follow up survey 30 and 100 days
after start of supplemental oxygen therapy for COVID19 infection.
Other: no intervention
no intervention
Inclusion Criteria:
1. Adult and paediatric patents (any age) who have received allogeneic stem cell
transplantation AND
2. Proven COVID19 infection as documented by PCR testing of nasal/ throat swab or NPA AND
3. Severe COVID 19 infection as defined by need for supplemental oxygen
Exclusion Criteria:
1. Patients beyond the first 72 hours of developing oxygen requirement or
2. Patients who have received cytokine targeting treatment before blood sampling or
3. Patients with a mild/moderate COVID19 infection (ie no need for supplementary oxygen)
Great Ormond Street Hospital NHS Foundation Trust
London, United Kingdom